LiverMultiScan, a device that can detect early liver disease using MRI, received FDA approval.
LiverMultiScan, a device that can detect early liver disease using MRI, received 510(k) clearance from the U.S. Food and Drug Administration, Perspectrum Diagnostics announced.
Since its introduction as a research device in 2014, LiverMultiScan is currently being used to assess primary endpoints in clinical trials for investigational therapies to treat non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, the company said in a release.
Perspectrum Diagnostics claims that LiverMultiScan is the only imaging test cleared to detect early-stage liver disease, offering a quantitative liver assessment in a non-invasive 15-minute MRI scan. The device analyzes the native properties of liver tissue and measures liver fat without the need for additional technology or contrast agents. The result is a highly detailed map of the whole liver, which makes it possible to precisely identify regions of disease, Perspectrum said.
“LiverMultiScan is a novel non-invasive imaging technology with the potential to dramatically change the way we approach diagnosis of liver disease,” Colonel Stephen A. Harrison, MD, FACP, FAASLD, Medical Corps USA, said in the release. “Recent published data suggest that this modality can rapidly differentiate normal liver from fibrotic non-alcoholic steatohepatitis and then accurately predict outcomes based on the liver, inflammation, fibrosis score.”[[{"type":"media","view_mode":"media_crop","fid":"43315","attributes":{"alt":"","class":"media-image media-image-right","id":"media_crop_8770959724425","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"4718","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 166px; width: 249px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":"Scan developed by LiverMultiscan that shows patient has steatohepatitis and high iron.","typeof":"foaf:Image"}}]]
The device is set for a formal launch at the 2014 American Association for the Study of Liver Disease Meeting, November 13-17, 2015 in San Francisco.
[[{"type":"media","view_mode":"media_crop","fid":"43316","attributes":{"alt":"","class":"media-image media-image-right","id":"media_crop_7718000684256","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"4719","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 155px; width: 200px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":"LiverMultiscan showing images of patient liver.","typeof":"foaf:Image"}}]]
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.